Emerging treatments
Neuroprotective agents
Neuroprotective agents have been studied in acute stroke, but results to date have been disappointing.[79]
Thiazolidinediones
One Cochrane review found that thiazolidinediones such as rosiglitazone and pioglitazone probably reduce recurrent stroke and total events of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke compared with placebo.[123]
[ 
]
The evidence for adverse events is inconclusive. Studies had a small number of patients and had methodological limitations. Some included patients with insulin resistance or abnormal glucose metabolism, while others excluded these patients. None of the trials specified the percentage of patients with TIA; therefore, the size of the effect on this group is unclear.[123]
Use of this content is subject to our disclaimer